Skip to main content
Premium Trial:

Request an Annual Quote

Johnson Pharmaceutical Research Institute Joins NaviCyte Consortium

Premium

SAN DIEGO, Calif.--NaviCyte, a wholly owned subsidiary of Trega Biosciences, entered an agreement with the R.W. Johnson Pharmaceutical Research Institute to collaborate on the development of NaviCyte's pharmacokinetic informatics tools for drug target selection. The research institute will provide data and make initial and milestone payments during development of NaviCyte's In Vitro Determination for Evaluation of Absorption (Idea) simulation software system and database. The tools are designed to enable prediction of pharmacokinetic outcomes in humans.

SmithKline Beecham, Genentech, Parke-Davis, and Schering Plough are also members of NaviCyte's consortium.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.